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The focus of this paper is explaining what current research is ongoing in AIDS and H I V treatment. The bio-
medical treatment of H I V and AIDS is based on three separate but integrated steps: use of antiviral drugs that 
will interfere with continuation of the H I V cycle; restoration of the immune system, and treatment of opportu-
nistic infections and cancers. With improved treatment, growing experience among health professionals in 
caring for HIV-infected patients, improved access to health care, and the decrease in number of new H I V in-
fections in the United States, Canada and Western Europe due to health education is part of the success in the 
fight against HIV. 
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In the summer of 1981, Dr. Michael Gottlieb of the Univer-
sity of California, Los Angeles described a rare form of 
pneumonia that was appearing in homosexual men. Along 
with this rare pneumonia, other reports of rare forms of can-
cers were appearing in homosexuals. This "syndrome" was 
at first dismissed as the "gay plaque" by the media and was 
believed it would soon vanish as fast as it emerged. That 
was twenty years ago. 
Origins and Course of the Human Immunological Virus 
It is believed by the established scientific and medical com-
munity (6,7) that the origins of the human immunodefi-
ciency virus (HTV) based on recent molecular epidemiolog-
ical data identified that HTV type 1 (HTV-1) evolved with a 
subspecies of chimpanzee, Pan troglodytes troglodytes, 
and was present with them for centuries. In this subspecies 
of chimpanzees, HTV-1 does not cause disease. The jump 
from the chimpanzees to humans most likely occurred in 
the sub-Sahara region of Africa where chimpanzees are 
butchered and consumed as a source of protein. The most 
likely mechanism of transmission of the virus would have 
been contamination of an open wound by butchering pro-
cess or the eating of under-cooked meat with open wounds 
in the mouth. This mode of transmission would have been 
sporadic and have escaped detection over the years, perhaps 
centuries. 
This intermittent HTV infection in rural Africa might have 
been passed on to an infected person's sexual partner and 
probably have resulted in the deaths of both victims, with-
out the further spread of the virus. Furthermore the on-
slaught of the opportunistic infections may have masked 
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the AIDS and HTV infection. These diseases are often rare 
in manifestation in a healthy individual. 
Human social and demographic conditions have changed 
for Africa, and world hence an epidemic was unleashed. 
These conditions are: migration from the rural regions to 
the urban centers, disintegration of the family due to the mi-
gratory nature of employment, with its attendant sexual 
promiscuity and extensive frequency of prostitutes, and 
contamination of blood supplies. Frequent civil uprisings 
and warfare in Central Africa most likely hasten the spread 
of this disease and others (7). 
The introduction of the epidemic to developed countries 
such as the United States, Canada and Western Europe has 
its roots in the "sexual revolution". The high-risk sexual 
practices, drug use and travel to "exotic" locations made 
free targets among the young adults in the 1970s and early 
1980s. The demographics for those effected from the HTV 
and AIDS epidemic in the United States has shifted from 
young homosexual males, intravenous drug users and he-
mophiliacs to the heterosexual population. 
Fauci (7) reports that it is believed that the HTV and AIDS 
epidemic in the United States and most developed countries 
has reached a plateau, because the level of new cases is no 
longer increasing exponentially. In fact, in the United 
States, Western Europe and Australia the number of cases 
of AIDS (per 100 000 population) has decreased overall 48 
%. The Center for Disease Control, Atlanta, GA, estimates 
that the half of the new cases of infection are young people 
of 25 years, or younger and are infected sexually. However, 
this reported plateau is deceptive. The number of infections 
among young heterosexual males and females is accelerat-
ing. 
Globally, we have a pandemic, no populated area is escap-
ing this infection and the sub-Saharan region is presently 
experiencing the greatest burden of the infection. The coun-
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tries formed from the former Soviet Union are experiencing 
an escalated number of new AIDS and HTV cases. I f dra­
matic preventive steps are not taken, the infection rate in the 
Indian subcontinent and Southeast Asia will eclipse the 
Black Death Plagues of Europe (1,3,4). 
Azidothymidine (AZT) 
The first drag to show significant benefit in treatment of 
AIDS patients was Azidothymidine (AZT) . It is still one of 
the primary drugs used in the treatment of AIDS. A Z T or 
commercially known as Retrovir is a nucleoside analog 
that blocks viral replication by inserting it's self in place of 
thymidine during DNA assembly. This inhibits viral DNA 
function and growth. Without A Z T , the average life expec­
tancy of an individual with opportunistic infections is less 
than six-seven months (6). A Z T has been proven in clinical 
tests and numerous studies show that the life expectancy for 
the patients generally will increase to one-two years, treat­
ment with A Z T for some individuals has led to some recov­
ery of the immune system function. 
This partial recovery is owed to the increased number of 
Thcipcr lymphocytes, opportunistic infections occur and 
some patients gain weight. A Z T is seldom used by itself 
today as a "monotherapy". In the beginning of the A I D S 
outbreak it was the only effective drug. However, the use 
of A Z T has not had its critics, in the mid 1990's the 
Concorde trial, held in England and France showed that 
in a blind study of HIV-infected individuals treated with 
A Z T and a group that received no treatment. There was 
difference in the rate of deaths between the AZT-treated 
and untreated individuals (6). The benefit of this drug is 
in the psychological well-being of the patients and im­
proving their perceived quality of life. The value of treat­
ing asymptomatic individuals in statistical analysis has 
resulted with a value of no significance according to 
these authors (6). 
Although A Z T has been effective in AIDS treatment, it has 
limitations: 
a) toxic side effects. The basis of this drug is to disrupt 
process of the DNA polymerase. However, in 
prolonged treatment some A Z T is incorporated into the 
cell's DNA leading to the death of the cell. Anemia 
results from killing red blood cells are a common side 
effect of A Z T treatment. 
b) inability to prevent the progression of HIV infection to 
full blown AIDS. This is due to the fact that the virus can 
mutate within its host. AZT-resistant HTV develops in 
the individuals who have been taking AZT. 
:) development of AZT-resistant variants. HTV has a rapid 
mutation capacity. Normally, the mutations take place 
in thepol gene, because this slows the growth rate down 
in the virus. However, the pol gene is less sensitive to 
AZT. 
3ven though A Z T has limitations, the effectiveness in 
;lowing down the progression of the virus has given pa-
ients and researcher time to study the HTV virus and im-
>rove patients' quality of life. Additionally, the A Z T drug 
has provided us with a mechanism that can inhibit HTV rep­
lication and serve as model for future research to improve 
the nucleoside analog drugs. The nucleoside analogs incor­
porate different DNA bases in the HTV DNA to inhibit its 
transcription. In a sense this acts to misspell the genetic in­
structions of the virus and hence halting its ability to func­
tion. 
Protease Inhibitors 
In 1996 a new class of anti-HIV drugs were developed and 
released for therapy: protease inhibitors (PI). This process 
is different from AZT; this agent inhibits HTV replication. 
PI targeted the viral enzyme protease. They work by bind­
ing to the HTV-protease enzyme and directly block its func­
tion. Protease inhibits the maturation of immature virus par­
ticles to maturity. Immature viral particles themselves are 
not infectious. Thus, drugs that inhibit the protease will in­
hibit the production of infectious HTV. A major advantage 
of using protease inhibitor is the reduction of the viral load 
in the blood to that below detection (6). 
Highly Affective Antiretroviral Therapy (HAART) 
When the protease inhibitors are combined with another 
regimen, highly affective antiretroviral therapy (HAART) , 
the effect is remarkable when compared to the nucleoside 
analog reverse transcriptase inhibitors (NRTIs) of the late 
1980s and early 1990s. The NRTIs therapy would consist 
of 1 or 2 nucliosides. The H A A R T regimen consists of 
three antiretroviral drags approved by the United States 
Food and Drag Administration (USFDA). This enhanced 
therapy consists of a nonnucleoside, a nucleoside and a pro­
tease inhibitor (9). 
Gallant (9) considers H A A R T as a revolutionary treatment 
of HTV. H A A R T will change the treatment of HTV to that 
of a manageable and chronic condition. The success of this 
therapy depends on early decisions that the patient and phy­
sician make together. The treatment should be delayed until 
the patient is educated and is willing to take responsibility to 
follow a strict schedule. Patient's discipline is crucial for the 
success of this therapy. Even with H A A R T and strict pa­
tient's regimen it will be impossible to achieve significant 
viral suppression. The problem with this combination of 
antiretroviral drags is the rapid mutations that occur with 
the HTV. 
PI interfere with the cleavage of polyprotein by the viral 
protease, which results in the production of noninfectious 
virions (9). On the other hand, the H A A R T regimen sup­
presses the viral load, which increases the CD4 cell count, 
improves the immunological function, delays clinical pro­
gression of the HTV and enhances patient's survivability. 
Presently, H A A R T is considered to be one of the most ef­
fective therapies for control of the HTV infection and AIDS 
symptoms (6,7,9,10). Studies by the former listed research­
ers have determined that H A A R T is one of the most 
cost-effective medical innovations. Gallant (9) claims 
H A A R T has significantly reduced mortality, hospitaliza­
tions, the incidence of opportunistic infections, and the use 
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home care resources, skilled nursing homes and hospices. 
Like any medical treatment, H A A R T has shortcomings. 
The short-term and long-term side complications include: 
hepatotoxic effects, diabetes, and a number of metabolic 
deviations that appear with no reason. 
Finally, other strains of drug resistant viruses are emerging 
and antiretroviral failure of some the antireretroviral agents 
has also emerged. Fauci (7) cites that the reason for 
H A A R T failure is due to the unfounded promise of success. 
The hope for success in his opinion encourages promiscuity 
and a return to unsafe sexual practices. 
Furthermore, patients with HIV-1 are being found to har-
bor up to 12 mutated strains with in themselves. Fauci (7) 
declares that the H A A R T itself is problematic in that many 
HIV-infected people cannot tolerate the toxic effects of the 
chemicals, or comply with the strict regimen that requires 
large numbers of pills, complicated dosage schedules to be 
considered with personal diets and fluid intakes, and chemi-
cal interactions between the drugs and other materials in-
gested. Even if the patients are willing to comply with tine 
scheduling and chemical concerns concerning HAART, 
they must have a low level of HIV-1 in their plasma. 
Testing for the HIV-1 virus is difficult, as it is notorious in 
its ability to hide in other tissues, and become latent. In a la-
tent fonn no drugs so far can treat it. 
Finally, HIV-1 is constantly in a mutable form. HTV-1 is 
able to change its phenotype, develop new strains that can 
evade the new drugs. The persistence of latent HIV mis-
leads the detectable HTV-1 levels in the plasma. The actual 
level of the HIV-1 level may be actually much greater that 
indicated. This fact necessitates in the simplest case that 
lifelong treatment may be necessary. The drugs used to treat 
HIV are expensive and difficult for the patient to tolerate for 
long periods. 
Other areas of research 
Current research conducted in other areas to make HIV 
treatment more patient-friendly is being directed towards: 
a) preventing the virus from entering the cell and preventing 
the integration of the provirus from entering the nuclear 
DNA; b) purging the latent virus from its latent reservoirs in 
cells and tissues, and c) finally, to boost HTV-specific im-
mune responses with in the body. 
Early diagnosis and treatment is important in controlling the 
HTV infection. The decision to start therapy for early stage 
patients must be made by the physician and patient to-
gether. The needs of the patient should be evaluated in ac-
cordance with advantages and disadvantages of treatment. 
Advantages of early treatment: 
1) Prevents loss of immune function and allows for 
effective immune reconstitution. 
2) I Viral mutation is reduced, and the potential for drug 
resistance is decreased. 
3) Patients with low baseline viral loads respond better to 
H A A R T , and "healthier patients" tolerate treatment 
easier. 
Disadvantages of early therapy: 
1) Early treatment will not make an asymptomatic patient 
feel better. 
2) The daily reminder of treatment may psychologically 
harm patients who can benefit from denial when it may 
be beneficial. 
3) Resistance to the drugs may develop earlier, therefore 
eliminating therapeutic options later. 
Predictions for patients who are started are not definite how 
effective their treatment will be i f it is delayed until symp-
toms if full blown AIDS appear. Patients who begin their 
treatment early lock themselves into a regimen that is de-
manding and may not be the best for them later. Many pa-
tients exhaust their treatment options prematurely, before 
they are able to show definite signs of improvement (9). 
The HTV vaccine 
Vaccines described by some authors (6) are being devel-
oped as those that will induce cellular mediated immunity 
and vaccines that are made from recombinant RNA that 
would induce the humoral immune response. Experiments 
with killed Simian immunodeficiency Virus (SIV) pre-
vented infection at low doses of live SIV virus, yet it was 
unsuccessful against higher doses or repetitive doses of live 
SIV. This situation, high doses, and repetitive doses is prob-
ably closer to natural routes of HIV infection. 
Research in development of the live vaccine against HIV is 
centered on the inactivation of the nef-gene, which is shared 
with the SIV and HTV virus (6). The immunity induced by 
the shared nej-mutant gene in an attenuated virus is stronger 
than those induced by the killed SIV. This indicates the 
safety of an attenuated HIV vaccine that will not induce 
AIDS. Vaccines designed to induce cellular immunity to 
HIV are also underway. Several trials are using combina-
tions of vaccines designed to induce cellular immunity with 
those that will initiate humoral immune responses. Fauci 
(7) reports that the National Institute of Health has recently 
assessed a series of vector vaccines from harmless viruses 
(e. g., canary pox) that has been altered to make HIV pro-
teins. The vectored vaccine with the purified HIV envelope 
protein has had encouraging results. The combination ap-
proach has appeared safe and has evoked both cellular and 
humoral immune responses that may provide protection 
from HIV infection. 
The development of a vaccine for HIV is not likely in the 
near future as there are many theoretic reasons that will be 
effective. HIV evades the immune system in an infected in-
dividual because of: the high mutation rate of the virus, par-
ticularly the en gene sequences; the ability of the virus to 
become latent in cells and to proliferate by cell to cell con-
tact. 
Additionally, there are differences between the HTVs found 
in various geographical regions. A successful vaccine 
would have to be tailor made for each strain. 
Biomedical efforts in research 
The biomedical efforts to treat HIV-infected individuals 
will continue to focus on three main points (6): antivirals 
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that will interfere with continued HIV infection; restoration 
of the immune system, and treatment of opportunistic in­
fections and cancers. 
Al l of the approved anti-HIV drugs work by interference 
with the processes carried out by the virus in protein tran­
scription and translation. This process reduces the viral load 
in patient's blood below the levels of detection, yet the fear 
of latency of the virus persists. The virus persists in the 
lymph nodes and macrophages much longer. 
Another direction of research in antiviral therapy is to inter­
fere with the ability of the virus to enter cells. Recombinant 
DNA procedures have been used to produce large quanti-
ies of CD4 proteins that will attract the HTV before it would 
alter the cell. This reduces the viral load but does not pre­
sent further infection in HTV individuals, 
t has been discovered that cells require a co-receptor, 
ZCR5, to allow for HTV infection. A small percentage of 
ie population lacks this receptor because of a genetic mu-
ition. Epidemiological studies have found that these indi-
iduals are resistant to HTV infection despite repeated expo­
ses. Therefore an effective anti-viral therapy could be tar-
eting the CCR5 co-receptor to prevent the spread of 
[TV-infection. 
wo new classes of potential antiviral agents recently de-
sloped and directed at the molecular level are antisense 
tolecules and ribozymes. The antisense molecules are 
eces of RNA or DNA molecules that will be inserted into 
е viral RNA of HTV. This disruption of the viral RNA 
ads to the destruction of the HTV, because the virus would 
it be able to replicate and build protein or other particles, 
bozymes are specialized antisense RNA molecules that 
mbine with HTV RNA, attack the RNA and cut the strand 
various sites destroying the virus. 
Restoration of the immune system 
е second targeted research area, restoration of the inl­
ine system, is important. Most of the symptoms resulting 
m AIDS are caused by the destruction of Т-helper cells. 
>od cell growth factors are currently being studied to 
nulate and regenerate the immune system. Interluekin 2 
-2) is the most promising in the restoration of the im-
ne systems. This is logical as IL-2 is necessary for the 
wth of both Т-helper and Т-killer cells. However, there 
two serious drawbacks. When administered it causes 
l fever and shock. Second, the treatment requires hospi-
ation, which is costly, and not feasible for developing 
rais to care for large number of patients. Bone marrow 
splants and blood transfusions are other avenues of in-
igation with limited expectations. The greatest technical 
ilem that lies here is that the fflV-irifected individual's 
/ generally attacks and destroys the healthy tissue. 
reatment of opportunistic infections and cancers 
third area of research is important as it improves the 
h of AIDS patients and enables their system to better 
ige the HTV infection. In terms of working with many 
i opportunistic infections and cancers that develop it is 
illenge, because many of these were diseases and in­
fections that were rarer than the HTV virus prior to the 
AIDS epidemic. 
Medical research reformed as a result of the HIV 
panemic 
The AIDS epidemic has left its indelible mark in many fac­
ets of science and society. Research has been effected by 
AIDS. Research is now perceived as a global and public 
concern. In the past, the Food and Drug Administration of 
the United States government would require years of re­
search and testing before an experimental drug would have 
been developed and implemented to be tested. Another re­
form in medical research is the parallel track. This allows 
patients to participate in research trials, even though they 
are unable to be at research centers. The patient is allowed 
to stay at home, his physician monitors his progress and re­
ports it to a medical research center. The local physicians 
record and report the results to a central pool. This greatly 
enhances the test population and brings the physicians in 
the mainstream of medical research. 
The parallel track of research provides the medical re­
searcher and the community a greater stake in the investiga­
tion and search for an answer in working with AIDS and 
HTV. 
Finally, the AIDS crisis has influenced upon medical re­
search in the development of surrogate endpoints. In clini­
cal trials, endpoints or standards are development to mark 
and compare the results of the research. When a disease is 
used, its cure or death of the individual has been tradition­
ally used. A clinical study of AIDS could take years to 
complete. To assist in the preliminary evaluation of HTV 
drugs, alternative measures have been developed and 
adopted. The most common surrogate endpoints are the pa­
tients' CD4 (Т-helper) lymphocyte cell count, the amount 
of viral protein (antigen) present in the blood, and the viral 
RNA that is present in the blood. The overall level of each 
of the surrogate endpoints reflects the overall health of the 
individual. 
Specifically targeted educational programs 
The role of public health education to appropriate popula­
tions does work. AIDS prevention campaigns to practice 
"safer-sex" in high-risk populations in the United States and 
Canada have resulted in a decrease in new cases of HTV in­
fection. Addressing specific populations is strongly en­
dorsed by the National AIDS Commission. 
Populations targeted for education: 
a) intravenous drug users. These individuals may be a 
conduit for spread of the infection into the heterosexual 
population. Clean needle programs have met resistance 
in many regions, for various reasons. Yet programs 
directed to this population had been underfunded and 
thus had limited success. 
b) ethnic groups. In the United States, Black-Americans 
and Hispanics represent a disproportionate number of 
AIDS patients as compared to those of European 
descent. In Europe, minority populations reflect the 
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same trend as the United States in HTV-infection 
incidence rates, 
c) reduction of backsliding behaviour. It is important to 
remind the general public continued adherence of safer 
behaviour. 
Continued education for health workers is important in this 
crisis. Uganda, one nation that has been especially affected 
by HIV-AIDS now provides for government sponsored 
warnings about AIDS. Schools and the public media 
openly discuss the promotion of safer-sex. The journal 
Natural Medicine (2) reported that the foreign-financed 
non-governmental organizations are given free reign to ed-
ucate people about AIDS. UNATDS is sponsoring research 
in a tropical microbiocide substance that a woman can use 
before intercourse as well as the female condom. These in-
terventions may help women to protect themselves from 
acquiring or passing the HIV infection if there is no other 
choice. Uganda and South Africa are establishing a collab-
orative AIDS policy that will apply pressure to the pharma-
ceutical industry to reduce the cost of medications. A single 
regimen of H A A R T consists of over 20 tablets, and will 
cost the individual thousands of dollars annually. 
C O N C L U S I O N 
This epidemic will require partnerships between public and 
private sectors as well as stronger political bonds between 
the nations of the world. Control of the HIV-AIDS pan-
demic will not be an easy task. No nation will be untouched. 
Education, behaviour modification, continued research and 
development of understanding and compassion for the vic-
tims of this disease will be the key to ending this "new age 
plague" (5-8,11). Free communication and unfettered med-
ical care for citizens regardless of nationality is vital. Unless 
methods of prevention, with or without a vaccine, are suc-
cessful, the worst pandemic will occur in this century. 
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